BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38129530)

  • 1. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.
    Jordan K; Chan A; Gralla RJ; Jahn F; Rapoport B; Ruhlmann CH; Sayegh P; Hesketh PJ
    Support Care Cancer; 2023 Dec; 32(1):53. PubMed ID: 38129530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
    Jordan K; Chan A; Gralla RJ; Jahn F; Rapoport B; Warr D; Hesketh PJ
    Support Care Cancer; 2017 Jan; 25(1):271-275. PubMed ID: 27501965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
    Scotté F; Schwartzberg L; Iihara H; Aapro M; Gralla R; Hesketh PJ; Jordan K; Chow R; Herrstedt J
    Support Care Cancer; 2023 Dec; 32(1):45. PubMed ID: 38114821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
    Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Clark-Snow R; Ruhlmann CH; Garcia-Del-Barrio MA; Schwartzberg L; Rapoport BL; Jahn F
    Support Care Cancer; 2023 Dec; 32(1):37. PubMed ID: 38110581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
    Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.
    Ruhlmann CH; Jahn F; Jordan K; Dennis K; Maranzano E; Molassiotis A; Roila F; Feyer P
    Support Care Cancer; 2017 Jan; 25(1):309-316. PubMed ID: 27624464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting.
    Ruhlmann CH; Jordan K; Jahn F; Maranzano E; Molassiotis A; Dennis K
    Support Care Cancer; 2023 Dec; 32(1):26. PubMed ID: 38097904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines.
    McKenzie E; Zaki P; Raman S; Olson R; McFarlane T; DeAngelis C; Chan S; Pidduck W; Razvi Y; Bushehri A; Chow E
    Support Care Cancer; 2019 Mar; 27(3):783-791. PubMed ID: 30607675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
    Herrstedt J; Roila F; Warr D; Celio L; Navari RM; Hesketh PJ; Chan A; Aapro MS
    Support Care Cancer; 2017 Jan; 25(1):277-288. PubMed ID: 27443154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
    Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
    Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents.
    Herrstedt J; Celio L; Hesketh PJ; Zhang L; Navari R; Chan A; Saito M; Chow R; Aapro M
    Support Care Cancer; 2023 Dec; 32(1):47. PubMed ID: 38127246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.
    Dupuis LL; Sung L; Molassiotis A; Orsey AD; Tissing W; van de Wetering M
    Support Care Cancer; 2017 Jan; 25(1):323-331. PubMed ID: 27565788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
    Roila F; Warr D; Hesketh PJ; Gralla R; Herrstedt J; Jordan K; Aapro M; Ballatori E; Rapoport B
    Support Care Cancer; 2017 Jan; 25(1):289-294. PubMed ID: 27510316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prophylaxis of chemotherapy-induced vomiting and nausea].
    Tóth J; Szántó J
    Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
    Einhorn LH; Rapoport B; Navari RM; Herrstedt J; Brames MJ
    Support Care Cancer; 2017 Jan; 25(1):303-308. PubMed ID: 27815710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy induced emesis: pathophysiology and prevention].
    Mailliez A; Bonneterre J
    Bull Cancer; 2010 Feb; 97(2):233-43. PubMed ID: 20051348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Hesketh PJ; Kris MG; Basch E; Bohlke K; Barbour SY; Clark-Snow RA; Danso MA; Dennis K; Dupuis LL; Dusetzina SB; Eng C; Feyer PC; Jordan K; Noonan K; Sparacio D; Somerfield MR; Lyman GH
    J Clin Oncol; 2017 Oct; 35(28):3240-3261. PubMed ID: 28759346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.
    Grunberg SM; Osoba D; Hesketh PJ; Gralla RJ; Borjeson S; Rapoport BL; du Bois A; Tonato M
    Support Care Cancer; 2005 Feb; 13(2):80-4. PubMed ID: 15599601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.